Q3 Earnings Estimate for MNPR Issued By HC Wainwright

Key Points

• HC Wainwright has issued Q3 2025 EPS estimates for Monopar Therapeutics, forecasting losses of ($0.51) per share.
• Monopar Therapeutics recently reported ($0.35) earnings per share for its latest quarter, surpassing analyst expectations of ($0.47).
• Several research firms have given Monopar a "Buy" rating, with a target price ranging from $60.00 to $74.00, indicating strong market interest.

Monopar Therapeutics Inc. (NASDAQ:MNPR - Free Report) - Investment analysts at HC Wainwright issued their Q3 2025 earnings per share (EPS) estimates for shares of Monopar Therapeutics in a research report issued to clients and investors on Tuesday, August 26th. HC Wainwright analyst A. Maldonado expects that the company will post earnings per share of ($0.51) for the quarter. HC Wainwright currently has a "Buy" rating and a $70.00 target price on the stock. The consensus estimate for Monopar Therapeutics' current full-year earnings is ($1.65) per share. HC Wainwright also issued estimates for Monopar Therapeutics' Q4 2025 earnings at ($0.54) EPS, FY2025 earnings at ($1.78) EPS, Q1 2026 earnings at ($0.58) EPS, Q2 2026 earnings at ($0.62) EPS, Q3 2026 earnings at ($0.47) EPS, Q4 2026 earnings at ($0.50) EPS, FY2026 earnings at ($2.12) EPS, FY2027 earnings at ($1.34) EPS, FY2028 earnings at ($0.74) EPS and FY2029 earnings at ($0.35) EPS.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last issued its quarterly earnings results on Tuesday, August 12th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.47) by $0.12.

MNPR has been the topic of a number of other reports. Cantor Fitzgerald reissued an "overweight" rating and issued a $74.00 price objective on shares of Monopar Therapeutics in a research note on Wednesday, August 27th. Chardan Capital reissued a "buy" rating and issued a $60.00 price objective on shares of Monopar Therapeutics in a research note on Wednesday, August 13th. Finally, Wall Street Zen raised Monopar Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Five research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $66.00.

Monopar Therapeutics Stock Down 2.6%

Shares of NASDAQ MNPR traded down $0.89 during trading on Thursday, reaching $33.27. The company had a trading volume of 16,460 shares, compared to its average volume of 39,660. The company's fifty day moving average price is $37.94 and its 200-day moving average price is $36.71. Monopar Therapeutics has a 12 month low of $2.29 and a 12 month high of $54.30. The stock has a market cap of $205.25 million, a P/E ratio of -9.99 and a beta of 1.20.

Insider Buying and Selling at Monopar Therapeutics

In other Monopar Therapeutics news, Director Kim R. Tsuchimoto sold 8,904 shares of the stock in a transaction on Monday, July 14th. The stock was sold at an average price of $40.00, for a total transaction of $356,160.00. Following the completion of the transaction, the director directly owned 11,486 shares of the company's stock, valued at approximately $459,440. This represents a 43.67% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Chandler Robinson sold 16,800 shares of the stock in a transaction on Monday, July 14th. The shares were sold at an average price of $40.00, for a total value of $672,000.00. Following the transaction, the chief executive officer directly owned 73,472 shares of the company's stock, valued at approximately $2,938,880. This trade represents a 18.61% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 42,504 shares of company stock valued at $1,700,160. Company insiders own 20.50% of the company's stock.

Hedge Funds Weigh In On Monopar Therapeutics

A number of large investors have recently made changes to their positions in MNPR. AlphaQuest LLC lifted its stake in Monopar Therapeutics by 46.8% during the second quarter. AlphaQuest LLC now owns 1,784 shares of the company's stock worth $64,000 after purchasing an additional 569 shares during the last quarter. Police & Firemen s Retirement System of New Jersey purchased a new position in Monopar Therapeutics during the 2nd quarter valued at about $34,000. JPMorgan Chase & Co. increased its holdings in Monopar Therapeutics by 1,821.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 1,921 shares of the company's stock valued at $69,000 after purchasing an additional 1,821 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. bought a new stake in Monopar Therapeutics during the 2nd quarter valued at approximately $80,000. Finally, New York State Common Retirement Fund bought a new stake in Monopar Therapeutics during the 2nd quarter valued at approximately $104,000. 1.83% of the stock is owned by institutional investors.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.